News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s RoActemra Wins U.K. Backing for More Arthritis Patients


10/7/2011 7:22:27 AM

Roche Holding AG (ROG) won the backing of the U.K. National Institute for Health and Clinical Excellence for the RoActemra rheumatoid arthritis drug after agreeing to provide a discount to the state-run medical system. RoActemra may be used at additional stages of treating the disease under new draft treatment guidelines, according to an e- mailed statement from the agency, known as NICE. Roche, based in Basel, Switzerland, must provide a discount on the medicine, which costs 9,295 pounds ($14,225) a year for a patient weighing about 70 kilograms (154 pounds). The level of the discount will remain confidential, NICE said.

Read at Bloomberg

comments powered by Disqus
Bloomberg
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES